Friday, 15 Feb 2019

You are here

Quarterly Canakinumab Reduces Gout Risk Without Affecting Uric Acid

The Annals of Internal Medicine reports that interleukin-1 (IL-1) inhibitor treatment is associated with a reduced risk of gout attacks - such are the findings of an anlysis of the CANTOS study previously reported at the Annual ACR 2017 meeting in Washington, DC. 

The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) study set out to assess whether antiinflammatory therapy, in the form of an IL-1 inhibitor canakinumab, could reduce risk of a future cardiovascular event in high risk individuals.  The results were reported in 2017 in the Lancet and NEJM and showed that canakinumab, 150 mg every 3 months significantly lowered rate of recurrent cardiovascular events (independent of lipid-level lowering) and it also reduced total cancer deaths, especially lung cancer. These effects were dose dependent.

Solomon et al. now reports on the effects on quarterly canakinumab on serum uric acid (sUA) levels and gout attacks in the 10,059 patients enrolled with a history of prior myocardial infarction and an elevated high-sensitivity C-reactive protein (hsCRP) level. Patients were followed for a median of 3.7 years.

Among placebo treated patients, the frequency of gout rose nearly 20 fold as sUA concentrations rose from 404.6 to 535.4 µmol/L or higher (gout risk rose from 0.28 to 5.94, respectively, per 100 person-years).

Receiving canakinumab was not associated with reductions in sUA over time but was associated with significantly reduced rates of gout attacks (hazard ratios ranged from 0.40 to 0.48).  Thus IL-1 inhibition lead to a 50-60% reduction in gout attacks along with a significant drop in CRP levels, but no effect on sUA levels. 

 While these data and other studies showing the efficacy of IL-1 inhibition in treating acute gout are encouraging, the cost of biologic therapy to either treat or prevent gout makes such therapies impractical for most.  Nonetheless, there may be benefits to targeting IL-1 and innate immunity in those at risk for gout.

Editors note: canakinumab is not FDA approved for use in gout. It is FDA approved for use in systemic JIA and Periodic Fever syndromes (CAPS, FMF, HIDS).

Disclosures: 
The author has received research/grant financial support on this subject

Rheumatologists' Comments

Barring the notable cost, I have contemplated a dose of Canakinumab prior to beginning Krystexxa (how to obtain it would be another issue), given the frequent flares associated with treatment. The 3 month benefit of a single dose may be all that is required?
The only proper start to this is to say you cannot take cost off the table - the annual cost of ILARIS is over $100,000. The list price of one injection is $16,769. I would love to take a rocket ship to work in 0.6 nanoseconds, but at a cost of $10,000 per trip Im afraid my wife would kill me, even if I could afford it. The reason I reported this was to encourage research and thinking about treating the innate immune response in Gout control. This research is a start....in my opinion. Thanks for mind bending conversations thats how we get to great for our patients! JC

More Like This

U.S. Gout Rates Remain Steady, but Substantial

Using data from 5,467 adults in the US in the National Health and Nutrition Examination Survey (NHANES) for the years 2007-2016, researchers found that the prevalence of gout and hyperuricemia has remained at 3.9%, having doubled from the 1960s to the 1990s, corresponding to an estimated 9.2 million adults with gout in 2015-2016.

Febuxostat Gets Reprieve from FDA Advisory Panel

On January 11, 2019 the FDA convened two advisory panels (the Arthritis Advisory Committee [AAC] and the Drug Safety and Risk Management Advisory Committee [DSaRM]) to consider the cardiovascular safety of febuxostat (Uloric) based on the 2018 “Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) study. 

The Vote

Only One-Third of Gout Patients Receive Urate-Lowering Drugs

The most recent analysis of National Health and Nutrition Examination Survey [NHANES] 2007-2016) data shows the prevalence of gout to be 9.3 million in the USA.

Data from 5,467 participants from NHANES 2015-2016, finds gout in 3.9% or  9.2 million US adults.  This includes 5.2% [5.9 million] of men and 2.7% [3.3 million] of  women with gout.

Sleep Apnea Increases Gout Risk

Both Gout and obstructive sleep apnea (OSA) comingle with a wide range of serious comorbidities. A matched retrospective cohort study from the UK Clinical Practice Research database shows those with OSA are at a higher risk of developing gout.

This report compared 15,879 patients with OSA versus 63,296 without; median follow‐up was 5.8 years.

Hepatic Safety of Urate Lowering Therapies in Gout

Lee and a group of Korean investigators have analyzed the comparative safety of allopurinol and febuxostat in a small cohort of gout patients with fatty liver disease (FLD) and found febuxostat had a lower risk for hepatotoxicity (defined as AST or ALT at least 3× the upper limit of normal) compared to allopurinol.